Effect of Honey Bee Venom on Proliferation of K1735M2 Mouse Melanoma Cells In-vitro and Growth of Murine B16 Melanomas In-vivo
Overview
Pharmacy
Authors
Affiliations
Bee venom has been reported to exhibit antitumour activity in-vitro and in-vivo. Apoptosis, necrosis and lysis of tumour cells were suggested as possible mechanisms by which bee venom inhibited tumour growth. The aim of this study was to investigate potential mechanisms by which bee venom inhibits K1735M2 mouse melanoma cells in-vitro and B16 melanoma, a transplantable solid melanoma in C57BL/6 mice, in-vivo. The proliferation of K1735M2 cells in-vitro was inhibited by bee venom in a concentration- and time-dependent manner. The inhibition was indicated by the arrest of the cell cycle at the G1 stage, as detected by flow cytometric measurements. The bee venom induced apoptosis-like cell death as identified by histological observations and by DNA fragmentation. In the in-vivo experiments, the bee venom (1.0, 3.0, 9.0 mg kg-1 of body weight, on days 1-12) was injected intraperitoneally into mice 24 h after the mice were inoculated with B16 cells. Inhibition of the solid tumour was observed. Apoptosis of the K1735M2 cells was suggested as the possible mechanism by which bee venom inhibited cell proliferation and induced K1735M2 cell differentiation in-vitro. The in-vivo experiment indicated that bee venom could be used as a chemotherapeutic agent against malignant tumours.
Ilhan H, Kabakci D, Secme M Med Oncol. 2024; 42(1):32.
PMID: 39699709 DOI: 10.1007/s12032-024-02584-2.
Antioxidant Activity and Mechanism of Action of Amwaprin: A Protein in Honeybee () Venom.
Kim B, Lee K, Jin B Antioxidants (Basel). 2024; 13(4).
PMID: 38671917 PMC: 11047345. DOI: 10.3390/antiox13040469.
Bee Venom: Composition and Anticancer Properties.
Gajski G, Leonova E, Sjakste N Toxins (Basel). 2024; 16(3).
PMID: 38535786 PMC: 10975291. DOI: 10.3390/toxins16030117.
Pharmacological properties and therapeutic potential of honey bee venom.
Ullah A, Aldakheel F, Anjum S, Raza G, Khan S, Tlak Gajger I Saudi Pharm J. 2023; 31(1):96-109.
PMID: 36685303 PMC: 9845117. DOI: 10.1016/j.jsps.2022.11.008.
Sevin S, Kivrak I, Tutun H, Uyar R, Ayaz F Appl Biochem Biotechnol. 2022; 195(5):3194-3205.
PMID: 36574137 DOI: 10.1007/s12010-022-04284-x.